Alpha 2.0
Login Register
» Articles » PMID: 25983996

Rituximab in Two Cases of Goodpasture's Syndrome

Overview
Journal NDT Plus
Publisher Oxford University Press
Specialty Nephrology
Date 2015 May 19
PMID 25983996
Citations 8
Authors
Birgit Schless
Suzan Yildirim
Daniel Beha
Frieder Keller
David Czock
Affiliations
Soon will be listed here.
Abstract

We describe the effects of rituximab in two patients with refractory Goodpasture's syndrome. After one single 1000 mg dose administration, rituximab did not appear to improve renal function in either of our cases. Polyoma virus-negative leukoencephalopathy, a probable toxic side effect of rituximab, was seen in our first patient.

Citing Articles

The Immunobiological Agents for Treatment of Antiglomerular Basement Membrane Disease.

Yamashita M, Takayasu M, Maruyama H, Hirayama K Medicina (Kaunas). 2023; 59(11).

PMID: 38004064 PMC: 10673378. DOI: 10.3390/medicina59112014.

Rituximab for the treatment of refractory anti-glomerular basement membrane disease.

Yang X, Jia X, Yu X, Cui Z, Zhao M Ren Fail. 2022; 44(1):1123-1129.

PMID: 35820833 PMC: 9291707. DOI: 10.1080/0886022X.2022.2097405.

Relapse of treated anti-GBM disease following hair dye use.

Povey J, Rutherford E, Levy J, Muniraju T BMJ Case Rep. 2021; 14(4).

PMID: 33795274 PMC: 8023745. DOI: 10.1136/bcr-2020-240543.

Use of Rituximab in Management of Rapidly Progressive Glomerulonephritis.

Cancarevic I, Malik B Cureus. 2020; 12(1):e6820.

PMID: 32181067 PMC: 7051118. DOI: 10.7759/cureus.6820.

Rituximab in treatment of anti-GBM antibody glomerulonephritis: A case report and literature review.

Uematsu-Uchida M, Ohira T, Tomita S, Satonaka H, Tojo A, Ishimitsu T Medicine (Baltimore). 2019; 98(44):e17801.

PMID: 31689860 PMC: 6946414. DOI: 10.1097/MD.0000000000017801.

References
1.
Wang X, Fogo A, Colon S, Giannico G, Abul-Ezz S, Miner J . Distinct epitopes for anti-glomerular basement membrane alport alloantibodies and goodpasture autoantibodies within the noncollagenous domain of alpha3(IV) collagen: a janus-faced antigen. J Am Soc Nephrol. 2005; 16(12):3563-71. DOI: 10.1681/ASN.2005060670. View
2.
Levy J, Turner A, Rees A, Pusey C . Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001; 134(11):1033-42. DOI: 10.7326/0003-4819-134-11-200106050-00009. View
3.
Matteucci P, Magni M, Di Nicola M, Carlo-Stella C, Uberti C, Gianni A . Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood. 2002; 100(3):1104-5. DOI: 10.1182/blood-2002-04-1271. View
4.
Sauter M, Schmid H, Anders H, Heller F, Weiss M, Sitter T . Loss of a renal graft due to recurrence of anti-GBM disease despite rituximab therapy. Clin Transplant. 2008; 23(1):132-6. DOI: 10.1111/j.1399-0012.2008.00912.x. View
5.
Lockwood C, Boulton-Jones J, Lowenthal R, Simpson I, PETERS D . Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis. Br Med J. 1975; 2(5965):252-4. PMC: 1673280. DOI: 10.1136/bmj.2.5965.252. View